Mentions
Extended reach
Total likes
Video views
AI synopsis
The analysis reflects a positive consensus on the importance of the first-in-human study, with comments referencing the assays used and previous FDA approvals of related therapies, which indicates shared interest and moderate engagement. The tone suggests optimism about the research's potential impact but remains cautious about its future clinical applications.
Most discussions recognize the significance of the new study on SAR445088, highlighting its potential and recent progress.
Posts show high interest, mentioning specific assays, previous approvals, and the novelty of the target pathway.
Participants reference methodology (assays used) and relate the findings to known treatments, indicating a moderate level of involvement.
The discussions acknowledge the potential implications for treating complement-mediated diseases, though they are still speculative at this stage.
Interesting work on a first-in-human study with a second-generation humanized IgG4 mAb against C1s: https://t.co/Fqm9eAqaCF The first-generation IgG4 blocking mAb against C1s, Sutimlimab, was approved by the FDA in 2022 for cold agglutinin disease!
In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience were used to determine the pharmacodynamic (PD) of SAR445088an anti-C1s humanized monoclonal antibody. https://t.co/XyJrwVs7Qc
RT @SvarLifeScience: In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience…
RT @SvarLifeScience: In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience…
RT @FPoppelaars: Interesting work on a first-in-human study with a second-generation humanized IgG4 mAb against C1s: https://t.co/Fqm9eAqa…
First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor: https://t.co/bXYjnHtkpA #complement #complementpathway
This study investigates SAR445088, a humanized antibody targeting the classical complement pathway, in a phase I trial with 93 healthy participants. The results show it is well tolerated, has a long half-life, and…
First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor: https://t.co/bXYjnHtkpA #complement #complementpathway
RT @SvarLifeScience: In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience…
RT @SvarLifeScience: In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience…
In a recently published first-in-human trial study, the WIESLAB CP and WIESLAB AP assays developed by #SvarLifeScience were used to determine the pharmacodynamic (PD) of SAR445088an anti-C1s humanized monoclonal antibody. https://t.co/XyJrwVs7Qc
RT @FPoppelaars: Interesting work on a first-in-human study with a second-generation humanized IgG4 mAb against C1s: https://t.co/Fqm9eAqa…
Interesting work on a first-in-human study with a second-generation humanized IgG4 mAb against C1s: https://t.co/Fqm9eAqaCF The first-generation IgG4 blocking mAb against C1s, Sutimlimab, was approved by the FDA in 2022 for cold agglutinin disease!